333 related articles for article (PubMed ID: 15042290)
21. Androgens and prevention of prostate cancer.
Sarvis JA; Thompson IM
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):271-7. PubMed ID: 18438176
[TBL] [Abstract][Full Text] [Related]
22. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
Opoku-Acheampong AB; Nelsen MK; Unis D; Lindshield BL
PLoS One; 2012; 7(1):e29068. PubMed ID: 22242155
[TBL] [Abstract][Full Text] [Related]
23. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
24. 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
Hamilton RJ; Freedland SJ
BMC Med; 2011 Sep; 9():105. PubMed ID: 21920036
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer: a serious disease suitable for prevention.
Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer chemoprevention.
Sandhu GS; Nepple KG; Tanagho YS; Andriole GL
Semin Oncol; 2013 Jun; 40(3):276-85. PubMed ID: 23806493
[TBL] [Abstract][Full Text] [Related]
27. Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?
Hoffman RM; Roberts RG; Barry MJ
J Gen Intern Med; 2011 Jul; 26(7):798-801. PubMed ID: 21222171
[TBL] [Abstract][Full Text] [Related]
28. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.
Wilt TJ; Macdonald R; Hagerty K; Schellhammer P; Tacklind J; Somerfield MR; Kramer BS
BJU Int; 2010 Nov; 106(10):1444-51. PubMed ID: 20977593
[TBL] [Abstract][Full Text] [Related]
29. [Chemoprevention of prostate cancer - a plea].
Schmitz-Dräger BJ; Bismarck E; Schöffski O; Fischer C
Aktuelle Urol; 2012 May; 43(3):157-61. PubMed ID: 22639024
[TBL] [Abstract][Full Text] [Related]
30. Overview of pivotal studies for prostate cancer risk reduction, past and present.
Andriole GL
Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625
[TBL] [Abstract][Full Text] [Related]
31. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.
Pinsky PF; Black A; Grubb R; Crawford ED; Andriole G; Thompson I; Parnes H
Cancer; 2013 Feb; 119(3):593-601. PubMed ID: 22893105
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention of prostate cancer: agents and study designs.
Thompson IM
J Urol; 2007 Sep; 178(3 Pt 2):S9-S13. PubMed ID: 17644117
[TBL] [Abstract][Full Text] [Related]
33. Molecular profiles of finasteride effects on prostate carcinogenesis.
Li J; Kim J
Cancer Prev Res (Phila); 2009 Jun; 2(6):518-24. PubMed ID: 19491289
[TBL] [Abstract][Full Text] [Related]
34. [Prevention of prostate cancer].
Wirth MP; Hakenberg OW
Dtsch Med Wochenschr; 2005 Sep; 130(36):2002-4. PubMed ID: 16143928
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention of prostate cancer.
Rittmaster RS
Acta Oncol; 2011 Jun; 50 Suppl 1():127-36. PubMed ID: 21604953
[TBL] [Abstract][Full Text] [Related]
36. RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Pitts WR
J Urol; 2005 Apr; 173(4):1433-4; author reply 1434-5. PubMed ID: 15758829
[No Abstract] [Full Text] [Related]
37. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
38. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
Azzouni F; Mohler J
Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Homma Y; Kaneko M; Kondo Y; Kawabe K; Kakizoe T
J Natl Cancer Inst; 1997 Jun; 89(11):803-7. PubMed ID: 9182979
[TBL] [Abstract][Full Text] [Related]
40. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
